231 result(s) found for: Triple negative breast cancer.
Displaying page 3 of 12.
| EudraCT Number: 2020-004610-35 | Sponsor Protocol Number: AL-2001 | Start Date*: 2021-03-16 | |||||||||||
| Sponsor Name:Allarity Therapeutics Europe Aps | |||||||||||||
| Full Title: Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Pr... | |||||||||||||
| Medical condition: Locally recurrent or metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) PL (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003723-21 | Sponsor Protocol Number: BSMO-2014-01 | Start Date*: 2015-05-27 |
| Sponsor Name:Belgian Society of Medical Oncology | ||
| Full Title: A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple ne... | ||
| Medical condition: Stage II and III triple negative breast cancer patients suitable for preoperative chemotherapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004715-41 | Sponsor Protocol Number: ODO-TE-B202 | Start Date*: 2019-12-24 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Odonate Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-002289-35 | Sponsor Protocol Number: SGNLVA-002 | Start Date*: 2018-04-02 | |||||||||||||||||||||
| Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
| Full Title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast C... | |||||||||||||||||||||||
| Medical condition: Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-004648-44 | Sponsor Protocol Number: MedOPP253 | Start Date*: 2020-07-06 | ||||||||||||||||||||||||||
| Sponsor Name:Medica Scientia Innovation Research S.L (MEDSIR) | ||||||||||||||||||||||||||||
| Full Title: A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pre... | ||||||||||||||||||||||||||||
| Medical condition: UNRESECTABLE LOCALLY ADVANCED OR METASTATIC RIPLE-NEGATIVE BREAST CANCER PATIENTS | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: PT (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-001328-17 | Sponsor Protocol Number: IMIB-HTF-2021-01 | Start Date*: 2021-09-23 |
| Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia | ||
| Full Title: Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. | ||
| Medical condition: Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-003029-16 | Sponsor Protocol Number: GO29505 | Start Date*: 2014-12-01 | |||||||||||
| Sponsor Name:Genentech, Inc. | |||||||||||||
| Full Title: A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast... | |||||||||||||
| Medical condition: Early stage triple negative breast cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003998-17 | Sponsor Protocol Number: ONCOGHdC2015-01 | Start Date*: 2017-02-16 |
| Sponsor Name:Grand Hôpital de Charleroi | ||
| Full Title: A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
| Medical condition: patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002435-15 | Sponsor Protocol Number: FiHM003 | Start Date*: 2017-08-10 |
| Sponsor Name:Fundación de Investigación HM Hospitales | ||
| Full Title: Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer | ||
| Medical condition: Supervised exercise regimen given during neoadjuvant chemotherapy for triple negative breast cancer patients. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003019-21 | Sponsor Protocol Number: IMMU-132-05 | Start Date*: 2017-12-14 | ||||||||||||||||||||||||||
| Sponsor Name:Immunomedics, Inc. | ||||||||||||||||||||||||||||
| Full Title: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who R... | ||||||||||||||||||||||||||||
| Medical condition: Relapsed/Refractory Triple-Negative Breast Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2007-006306-25 | Sponsor Protocol Number: IEO S385/607 | Start Date*: 2008-05-22 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: A phase II study of primary chemotherapy with pegylated liposomal doxorubicin (Caelyx), Cisplatin, and Fluorouracil (CCF) followed by metronomic Capecitabine, Cyclophosphamide and Sorafenib (CCS) i... | |||||||||||||
| Medical condition: Patients with histologically proven locally advanced primary breast cancer (cT2-T3-T4 a-d, N0-3c, M0) or patients with histologically proven local recurrence after breast conserving surgery (rT1-T... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004796-23 | Sponsor Protocol Number: REP0114 | Start Date*: 2015-07-06 | |||||||||||
| Sponsor Name:Dompé Farmaceutici s.p.a. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Can... | |||||||||||||
| Medical condition: Metastatic triple negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) PL (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005170-65 | Sponsor Protocol Number: MK-8109-004 | Start Date*: 2014-10-23 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced ... | |||||||||||||
| Medical condition: Triple Negative Breast Cancer (advanced breast cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005209-23 | Sponsor Protocol Number: CA163139 | Start Date*: 2008-03-21 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/... | |||||||||||||
| Medical condition: BREAST CANCER, FIRST LINE | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001669-11 | Sponsor Protocol Number: IFOM-CPT008/2022/PO007 | Start Date*: 2022-09-22 | |||||||||||||||||||||
| Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano | |||||||||||||||||||||||
| Full Title: Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRiBRAVE Trial. | |||||||||||||||||||||||
| Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2006-005000-13 | Sponsor Protocol Number: EMR200027-051 | Start Date*: 2007-03-30 | |||||||||||
| Sponsor Name:Merck KGaA | |||||||||||||
| Full Title: Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”) | |||||||||||||
| Medical condition: Metastatic breast cancer PR-negative, ER-negative and HER-2 negative | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IE (Completed) BE (Completed) ES (Completed) AT (Completed) PT (Completed) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001155-13 | Sponsor Protocol Number: GBG-99-GeparTREIZE | Start Date*: 2019-04-02 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:GBG Forschungs GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Early-staged triple-negative breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-001864-12 | Sponsor Protocol Number: IRFMN-BRC-6992 | Start Date*: 2018-02-09 | ||||||||||||||||||||||||||
| Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri | ||||||||||||||||||||||||||||
| Full Title: International, multicenter, phase II, randomized, parallel-arm trial investigating the role of two different metronomic chemotherapy regimens in locally advanced or metastatic triple negative breas... | ||||||||||||||||||||||||||||
| Medical condition: Locally advanced or metastatic triple negative breast cancer (TNBC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-004989-23 | Sponsor Protocol Number: G200901 | Start Date*: 2015-08-20 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:GTx, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: LT (Completed) GB (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date*: 2016-08-01 | |||||||||||
| Sponsor Name:GBG Forschungs GmbH | |||||||||||||
| Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
| Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
